BioSpace News Archive

Generate Life Sciences today announced it is donating a Sepax 2 S-100 cell bioprocessing system manufactured by Cytiva to Rutgers Cancer Institute of New Jersey to support investigation of the potential efficacy of cord blood infusions in a variety of pediatric brain injuries.

Vizzia Technologies has expanded its Environmental Monitoring solution with new technology that is fully compliant with key federal guidelines from the U.S. FDA and the U.S. Department of Commerce National Institute of Standards and Technology.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a clinical collaboration to evaluate elzovantinib.

Research published today in the journal Frontiers in Medicine found that Gazelle™, a diagnostic platform from Hemex Health, has 99% accuracy in diagnosing sickle cell disease (SCD).

Baxter to Present at Credit Suisse 30 th Annual Virtual Healthcare Conference

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing and global contract research services, announced that it plans to release its third quarter 2021, financial results on Thursday, November 4, 2021.

Arch Therapeutics, Inc. today provided a corporate update at the LD Micro Main Event XIV investor conference in Los Angeles, CA.

PDS Biotechnology Corporation will release financial results for the third quarter of 2021 on Wednesday, November 10, 2021, before the market opens.

Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2021 financial results on Wednesday, November 3rd , before the market opens.

Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis